Several other brokerages have also issued reports on AZN. Barclays reaffirmed an overweight rating and issued a GBX 6,600 ($86.24) target price (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research note on Friday, August 10th. HSBC set a GBX 4,840 ($63.24) target price on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, August 15th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research note on Wednesday, August 15th. Credit Suisse Group reaffirmed an outperform rating on shares of AstraZeneca in a research note on Tuesday, October 23rd. Finally, Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research note on Tuesday, October 23rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Hold and an average price target of GBX 5,831.89 ($76.20).
Shares of LON AZN traded up GBX 79 ($1.03) during mid-day trading on Thursday, hitting GBX 6,172 ($80.65). The company’s stock had a trading volume of 1,976,706 shares, compared to its average volume of 2,310,000. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.